In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Exo Therapeutics, Inc.

http://exo-therapeutics.com/

Latest From Exo Therapeutics, Inc.

Finance Watch: Four New VC Funds Provide $1.3bn For Biotech Start-Ups

Private Company Edition: Newpath Partners’ second fund totals $350m, Merck KGaA committed €600m to M Ventures, Eir Ventures raised €122.3m and Breakout Ventures has $112.5m. Recent financings were led by SOTIO ($317.5m), Odyssey ($218m), Avistone ($200m) and Acepodia ($109m).

Financing Innovation

Finance Watch: Exo Raises $78m To Advance Exosite-Targeting Small Molecules

Also, Atlas Venture and Advent France Biotechnology raise new venture capital funds, Corium secures $235m in debt to commercialize ADHD drug and CBMG leads recent VC financings with $120m series A round.

Financing Innovation

Finance Watch: Three Neurology-Focused Firms Raise VC Mega-Rounds

Private Company Watch: Neuron23, Neurogene and Locanabio each raised $100m or more, highlighting increased investor interest in novel approaches to neurological diseases. Also, CRO dMed raised $100m and MinervaX brought in $57m for its vaccine to protect newborns. 

Financing StartUps and SMEs
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
UsernamePublicRestriction

Register